Keyword: Mayne Pharma

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

Kroger and other grocery chains are suing Mylan, Teva, Endo and many other companies for an "overarching conspiracy" to artificially inflate prices.

Price-fixing allegations against generics makers just keep piling up, with Mylan, Teva and other players targeted in yet another lawsuit.

The Q1 performance from Novartis’ Sandoz—the second-leading player in the generics space—spells more bad news in the knockoffs arena.

Maryland lawmakers have passed a bill aimed at taking on “unconscionable” pricing practices, but the industry still hopes to derail it.

Twenty states have unveiled a civil lawsuit accusing half a dozen drugmakers, including Mylan, Teva and Heritage, with generic drug price fixing just a day after the DOJ filed charges against two Heritage execs.

Australia’s Mayne Pharma is investing about $90 million to expand its capacity at plants in the U.S. and Australia as part of a move to become a notable player in the U.S. Now it has a bunch of new products to manufacture in them.

Teva’s massive deal to buy Allergan’s generics business continues to ripple its way through the industry. Australia’s Mayne Pharma has scooped up 42 products from the two companies for $652 million, leaping 50 spots in the U.S. generics scene into the top 25 biggest players.

Australia-based Mayne Pharma ($MYX) has been expanding its manufacturing in the U.S. to build up capacity in the world’s richest market. Now it will expand in Australia, also as part of its U.S. efforts.